Phase I/II Study of Adoptive Immunotherapy After Allogeneic HCT With Virus Specific CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T Cell Receptor for Patients With Relapsed AML
Latest Information Update: 27 Jun 2022
At a glance
- Drugs JTCR 016 (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 31 May 2022 Status changed from active, no longer recruiting to discontinued.
- 29 Oct 2020 Planned End Date changed from 1 Oct 2030 to 1 Sep 2029.
- 29 Oct 2020 Planned primary completion date changed from 1 Oct 2020 to 1 Sep 2029.